1. Introduction {#s0010}
===============

The ultimate goal of cancer therapeutics is to increase the survival time and the life quality of the patient by reducing the unintended harmful side-effects [@bib0010]. Although, the medical science and biomedical engineering advanced to a significant extent, the therapeutic development of anti-cancer strategies is often limited by administration problem of the drugs [@bib0015]. In recent years, with the development of cancer nanotechnology, researchers have focused on developing nano-scale anticancer drug carriers for improving therapeutic efficacy as well as reducing unwanted side effects [@bib0020], [@bib0025], [@bib0030]. Research on graphene highlights a new two-dimensional (2D) nanosystem in the area of biomedicine [@bib0035], [@bib0040], [@bib0045], just like graphene, layered molybdenum disulfide (MoS~2~) is another 2D nanostructure [@bib0050], [@bib0055]. MoS~2~ is composed of two layers of sulfur atoms and a layer of molybdenum atoms, and a layer of molybdenum atoms is sandwiched between the two layers of sulfur atoms [@bib0060], [@bib0065], [@bib0070]. Compared with graphene, MoS~2~ has many similar electronic, optical, mechanical and chemical properties, making it have a great potential in the area of biomedicine [@bib0075]. Graphene had been successfully explored its applications as biosensors, photothermal agents, drug delivery platforms, and tissue engineering scaffolds [@bib0065], [@bib0080]. The success of graphene encouraged the exploration of MoS~2~ for biomedical applications. So far, there are only a few reports using MoS~2~ in the area of biomedicine, especially in cancer diagnosis and treatment applications. Liu et al. used PEGylated MoS~2~ as a multifunctional theranostic agent for *in vivo* dual modal CT/photoacoustic imaging guided photothermal therapy, and achieved a good tumor theranostic efficacy [@bib0085]. However, the above system did not explore the application of MoS~2~ as an antitumor drug delivery platform, and the biological safety of MoS~2~ *in vivo* had not been explored to our best knowledge.

MoS~2~ has a huge specific surface area, high thermal and chemical stability, and the surface layers of sulfur atoms make MoS~2~ have a good adsorption capacity to small molecules [@bib0090]. The above properties give MoS~2~ great advantages as a drug delivery platform. However, the inherent hydrophobicity limit its use in biology and thus lead to the research in searching water-soluble MoS~2~ derivatives [@bib0095]. For drug delivery applications, PEGylation has been widely used to extend the circulation time of a drug system, allowing the drug more time to accumulate in the tumor via the enhanced permeability and retention effect [@bib0100], [@bib0105]. So in this study, PEG-modified MoS~2~ was used to explore its applications in drug delivery.

Photothermal therapy (PTT) uses light absorbing agents to convert optical energy into heat, leading to the thermal ablation of cancer cells [@bib0110], [@bib0115]. In recent years, PTT as a minimally invasive, controllable, and highly efficient treatment method has drawn widespread attention. MoS~2~ nano sheets exhibit strong visible to NIR absorbance owing to the surface plasmin resonance (SPR) effect, making it powerful agents in PTT cancer treatment [@bib0110]. In this study, we hypothesized that exposure to a focused external NIR light (808 nm) would lead to significant heat release by the functionalized MoS~2~, allowing it to serve directly as an anticancer therapeutic agent.

Another advantage of MoS~2~ is its novel X-ray imaging ability [@bib0120], [@bib0125]. X-ray computed tomography is widely used for screening and diagnosis of various pathologies including cancer. The ability to visualize deep structures in the body is the main advantage of X-ray imaging. Just like gold, molybdenum also has a high atomic number and a high absorption coefficient giving MoS~2~ great contrast per unit weight [@bib0125]. In this study, MoS~2~ was also used as a X-ray imaging contrast agent for tumor diagnosis.

An ideal drug delivery system should not only accumulate drugs in tumor tissue, enter into the cancer cells through endocytosis, but also need to escape from the endosomes, therefore minimizing enzymatic hydrolysis of antitumor drugs while the therapeutic effects are maximized. Endosome escape technology had been widely used in antitumor drug delivery system [@bib0130], [@bib0135], the pH sensitivity induced surface protonated effect of the drug delivery system is very common mean for endosome escape [@bib0140], [@bib0145], but the NIR light induced endosome escape system was rare. A MoS~2~ based drug delivery system was developed, and its NIR induced endosome escape was realized in this study.

In this work, a polyethylene glycol (PEG2000) modified MoS~2~ (MoS~2~-PEG) with high aqueous solubility, neutral pH and accessibility to further modification, was synthesized, characterized and explored its applications in drug delivery, PTT, X-ray diagnosis and endosome escape induced by NIR. Doxorubicin (DOX), one of the most effective drugs against a wide range of cancers, was employed as the model drug and loaded onto MoS~2~-PEG with high efficacy. Herein, taking advantages of the endosome escape property, potential in PTT, drug delivery and X-ray imaging ability of MoS~2~-PEG, a multi-functional drug delivery system (MoS~2~-PEG/DOX) ([Fig. 1](#f0010){ref-type="fig"}) was developed and characterized by transmission electron microscopy (TEM), dynamic laser scattering (DLS), Fourier transmission infrared spectroscopy (FTIR). NIR induced endosome escape, PTT, tumor-targeting and photothermal-chemo therapeutic efficacy of MoS~2~-PEG/DOX was evaluated using MCF-7 cells and tumor-bearing mice models, furthermore, *in vivo* X-ray imaging of tumor-bearing mice using MoS~2~-PEG is also conducted.Fig. 1Scheme of MoS~2~-PEG/DOX and its biofunctions.Fig. 1

2. Materials and methods {#s0015}
========================

2.1. Materials {#s0020}
--------------

Molybdenum disulfide (MoS~2~, purity \> 95%) were purchased from DK nano Co. Ltd Beijing. Doxorubicin (DOX, 20120503, purity \> 98%) was gotten from Beijing Yi-He Biotech Co. Ltd. Thioglycollic acid (HSCH~2~COOH, 70% in water), NH~2~-PEG2000-OCH~3~, N-(3-dimethylamino propyl-N0-ethylcar-bodiimide) hydrochloride (EDC∙HCl), IR 783 dye and dimethyl sulfoxide (DMSO) were obtained from Sigma-Aldrich Co. LLC. Sulforhodamine B (SRB), RPMI 1640 cell culture medium, penicillin, streptomycin, fetal bovine serum (FBS), and heparin sodium were bought from Gibco Invitrogen.

2.2. Synthesis of MoS~2~-PEG/DOX {#s0025}
--------------------------------

Synthesis of MoS~2~ nanosheets. Two-dimensional MoS~2~ nanosheets were prepared by the chemical exfoliation method according to the literature [@bib0125] ([Fig. 2](#f0015){ref-type="fig"}). In brief, 50 mg MoS~2~ and 2 g NaCl were mixed and grinded for 4 h, and then NaCl was removed by repeating adding water and centrifugation. The treated MoS~2~ (50 mg) was added to 20 ml of oleum, after stirring at 90 °C for 12 h, the result product (MoS~2~ nanosheets) was washed by centrifugation for several times with deionized (D.I.) water, and dried in vacuum for 12 h.Fig. 2A schematic illustration of MoS~2~-PEG/DOX nanocomposite preparation.Fig. 2

Synthesis of MoS~2~-COOH. The MoS~2~ nanosheets (50 mg) was added to 20 ml of mercapto acid, after stirring at room temperature under protection of Ar for 24 h, the result product (MoS~2~-COOH) was washed by centrifugation for several times with deionized (D.I.) water, and dried in vacuum for 12 h.

Conjugation of PEG to MoS~2~-COOH. MoS~2~-COOH (50 mg) was suspended with NH~2~-PEG2000-OCH~3~ (200 mg) in a pH 7.4 phosphate buffered saline (PBS) solution (50 ml), EDC⋅HCl (80 mg), and then NHS (35 mg) was added. The mixture was allowed to react at room temperature for 48 h, after which the conjugate was precipitated using 200 ml of anhydrous ethanol, then the precipitate was purified by repeated rinsing with ethanol and filtrations to remove the unreacted reagents to obtain MoS~2~-PEG. The resulting solid products were dried in vacuum at 60 °C for 24 h.

DOX loading. MoS~2~-PEG (50 mg) was added to DOX water solution (20 ml) containing DOX (150 mg) and sonicated at room temperature for 2 h and then sonicated using an ultrasonic cell disruption system (400W, 10 times), finally the nanosuspension was centrifuged to remove free DOX. The entire process was carried out in the dark, and the resulting MoS~2~-PEG/DOX nanosuspension was stored at 4 °C in the dark until use. The amount of DOX loaded onto MoS~2~-PEG was measured at 490 nm by UV-VIS spectrometer.

2.3. Characterization {#s0030}
---------------------

DLS (Zetasizer Nano ZS-90, Malvern, UK) and TEM (Tecnai G2 20, FEI) were used for characterizing zeta potential and morphological of MoS~2~-PEG/DOX, respectively. The optical properties of MoS~2~-PEG/DOX were characterized using a UV-VIS spectrometer (Lambda 35, Perkin-Elmer, USA). FT-IR spectra were recorded on a Nicolet iS10 spectrometer (Thermo). The photothermal efficacy of MoS~2~-PEG/DOX was performed using a thermal infrared imager (T200, Fluke). The *in vivo* fluorescence and X-ray images were conducted on a small animal *in vivo* imaging system (Bruke).

2.4. NIR induced thermal effect of MoS~2~-PEG {#s0035}
---------------------------------------------

For photothermal therapy, a NIR laser (808 nm, 1 or 2 W/cm^2^) was used. MoS~2~-PEG in water (0.2 ml) at 10 µg/ml was illuminated with an 808 nm, continuous-wave NIR with the power density of 1 W/cm^2^ or 2 W/cm^2^. The temperature was measured by a thermal infrared imager (T200, Fluke).

2.5. DOX release from MoS~2~-PEG/DOX {#s0040}
------------------------------------

MoS~2~-PEG/DOX (1 ml) was sealed in dialysis membranes (MW cutoff 1000, Spectrapor). The dialysis bags were incubated in 10 ml PBS buffer at 37 °C with a stirring rate of 100 r/min. A 200 µl portion of the aliquot was collected from the incubation medium at predetermined time intervals, and the released DOX was quantified by UV-vis spectrophotometer at 490 nm. The DOX release studies were performed in triplicate for each sample.

2.6. Cellular experiments {#s0045}
-------------------------

Cell culture. MCF-7 human breast cancer cell line was obtained from Chinese Academy of Sciences Cell Bank (Catalog No. HYC3204). Cells were cultured in normal DMEM culture medium with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin in 5% CO~2~ and 95% air at 37 °C in a humidified incubator.

Cellular uptake. Intracellular uptake of DOX and MoS~2~-PEG/DOX were performed with MCF-7 cells. MCF-7 cells were seeded at 5 × 10^4^ cells/well on glass cover slips in 6-well plates. When cells reached 70% confluence, they were treated with DOX (10 µg/ml) and MoS~2~-PEG/DOX (DOX concentration: 10 µg/ml and MoS~2~-PEG concentration: 14.5 µg/ml) for 0.5, 2 and 6 h, respectively. After washing three times with PBS, the cells were imaged by a Fluorescence Microscope (Zeiss LSM 510).

NIR induced endosome escape. MCF-7 cells were seeded at 5 × 10^4^ cells/well on glass cover slips in 6-well plates. When cells reached 70% confluence, they were treated with MoS2-PEG/DOX (DOX concentration: 10 µg/ml and MoS2-PEG concentration: 14.5 µg/ml) for 2 h, after incubation, cells were washed twice with PBS, and then a NIR laser (808 nm, 2 W/cm^2^, 5 min) was delivered to culture dish. After irradiation, the DOX signal in MCF-7 cells were acquired using a Fluorescence Microscope (Zeiss LSM 510).

*In vitro* PTT. To investigate the PTT effect of MoS~2~-PEG on cancer cells, the MCF-7 cells were cultured and lifted as described above before seeding (1 × 10^4^) into 96-well plates and incubating for 24 h. The medium then was replaced with fresh medium containing various concentrations of free MoS~2~-PEG for 6 h, the cells were or were not irradiated with a NIR laser (808 nm, 2 W/cm^2^) for 5 min. At last a standard cell viability assay using SRB was conducted. MCF-7 cells were seeded into a 6-well plates, after incubating with MoS2-PEG (10 µg/mL) for 6 h, PI was loaded into the cells. After 30 min incubation, a NIR laser (2 W/cm^2^) was delivered to the center of the plate for 5 min. At last, fluorescence images in red field were acquired using a Fluorescence Microscope (Zeiss LSM 510).

*In vitro* photothermal-chemotherapy. To investigate combination therapeutic effect of PTT and chemotherapy of MoS~2~-PEG/DOX, MCF-7 cells were seeded at 1 × 10^4^ cells/well on glass cover slips in 96-well plates for 24 h. The medium then was replaced with fresh medium containing free DOX and MoS~2~-PEG/DOX (the same DOX concentration) for 6 h, the cells were or were not irradiated with a NIR laser (808 nm, 2 W/cm^2^) for 5 min. At last a standard cell viability assay using SRB was conducted.

Cells apoptosis assay. Apoptosis was monitored by an Annexin-V-Fluos Staining kit (Sigma-Aldrich Co. LLC). MCF-7 cells were treated with free DOX (5 µg/ml), MoS~2~-PEG (7.3 µg/ml) and MoS~2~-PEG/DOX (DOX concentration: 5 µg/ml, MoS~2~-PEG concentration: 7.3 µg/ml) for 6 h, the cells were or were not irradiated with a NIR laser (808 nm, 2 W/cm^2^) for 5 min, then trypsinized, washed with PBS, and re-suspended in binding buffer (10 µM HEPEs/NaOH, pH 7.4, 140 µM NaCl, and 2.5 µM CaCl~2~). After adjusting cell density to 1 × 10^6^ cell/ml, 1 µl of recombinant human anti-Annexin V-FITC and 2 µl of propidium iodide (PI) were added to 100 µl of cell suspension, mixed by a vortex and incubated at room temperature in the dark for 15 min. Finally, 400 µl binding buffer was added to the above cells and subsequently analyzed by Flow Cytometry (FCM, Epics XL.MCL).

2.7. *In vivo* experiments {#s0050}
--------------------------

Xenograft tumor mouse model. All animal experiments were performed under a protocol approved by Henan laboratory animal center. The S180 tumor models were generated by subcutaneous injection of 2 × 10^6^ cells in 0.1 ml saline into the right shoulder of female BALB/c mice (18--20 g, Henan laboratory animal center). The mice were treated when the tumor volume reached 60 to 100 mm^3^ (\~6 days after tumor inoculation).

Toxicity test of MoS~2~-PEG. For the acute toxicity, 120 mg/kg, 60 mg/kg and 10 mg/kg of MoS~2~-PEG (all in 0.2 ml solution) were intravenously injected into tumor-bearing mice (6 mice per group). For the long-term toxicity, 20 mg/kg of MoS~2~-PEG were intravenous injected into tumor-bearing mice (6 mice per group) every 2 d for 14 d, the number of hemocytes and the transaminase in blood were determined after 14 d treatment.

*In vivo* biodistribution of MoS~2~-PEG. A near-infrared dye (IR783) was used to mark MoS~2~-PEG: IR783(50 µg) was added to MoS~2~-PEG nanosuspension (1 mg/ml, 5 ml) and ultrasonicated with ultrasonic cell disruption system to obtain MoS~2~-PEG/IR783. Excess IR783 was removed by Sephadex G-25 column (Sigma Aldrich Co. LLC). 0.2 ml of MoS~2~-PEG/IR783 were intravenously injected into tumor-bearing mice, and the whole body fluorescence imaging were performed at 1 min, 30 min, 4 h, 8 h and 24 h after injection.

Biodistribution of DOX. 0.2 ml of DOX (5 mg/kg) and MoS~2~-PEG/DOX (DOX: 5 mg/kg, MoS~2~-PEG: 7.3 mg/kg) were intravenously injected into tumor-bearing mice (6 mice per group). After injection for 0.5, 4, 8 and 12 h, the mice were killed to collect heart, liver, spleen, lung, kidney and tumor, weighed, and homogenized in buffer (methanol to saline ratio, 1:1). DOX in tumors were determined by high performance liquid chromatography (HPLC, 1100 Agilent, USA) under the following chromatographic conditions: an Eclipse XDB-C18 column (150 mm × 4.6 mm, 5.0 µm); mobile phase sodium acetate solution (0.02 mol/L)/acetonitrile 80:20; column temperature 40 °C; fluorescence detector with the excitation and emission wavelengths set at 475 nm and 525 nm, respectively; flow rate 1.0 mL/min; and injection volume 20 µL.

*In vivo* antitumor effect. For the *in vivo* antitumor experiments, the tumor-bearing mice were divided into seven groups (six mice per group), minimizing the differences of weights and tumor sizes in each group. The mice were administered with (1) saline (0.2 ml), (2) saline/NIR (0.2 ml), (3) MoS~2~-PEG (7.3 mg/kg), (4) DOX (5 mg/kg), (5) MoS~2~-PEG/DOX (DOX: 5 mg/kg, MoS~2~-PEG: 7.3 mg/kg), (6) MoS~2~-PEG/NIR (7.3 mg/kg, 808 nm laser, 2 W/cm^2^, 5 min) and (7) MoS~2~-PEG/DOX/NIR (DOX: 5 mg/kg, MoS~2~-PEG: 7.3 mg/kg, 808 nm laser, 2 W/cm^2^, 5 min) were intravenously injected into mice via tail vein every 2 days, respectively, the irradiating groups were exposed to 808 nm laser at 8 h post-injection. The mice were observed daily for clinical symptoms and the tumor sizes were measured by a caliper every other day and calculated as the volume = (tumor length) × (tumor width)^2^/2. After treatment for 14 days, the mice were killed to collect tumor tissue for H&E staining. Morphological changes were observed under microscope (Zeiss LSM 510).

*In vivo* X-ray imaging. For *in vivo* X-ray imaging, the tumor-bearing mice were intravenously injected with MoS~2~-PEG/DOX (DOX: 10 mg/kg, MoS~2~-PEG: 14.5 mg/kg), after injection for 0.5, 4, 8 and 12 h, X-ray imaging was conducted on a small animal *in vivo* imaging system (Bruke). Iohexol (a clinical X-ray contrast agent, 240 mg/ml, 0.1 ml) and MoS~2~-PEG (8 mg/ml, 0.1 ml) were subcutaneously injected into a health mice, and the X-ray imaging effect was also tested by the small animal *in vivo* imaging system (Bruke).

2.8. Statistical analysis {#s0055}
-------------------------

Quantitative data are expressed as mean ± SD and analyzed by use of Student\'s t test. *P* values \< 0.05 were considered statistically significant.

3. Results and discussions {#s0060}
==========================

3.1. Synthesis and characterization of MoS~2~-PEG/DOX {#s0065}
-----------------------------------------------------

The large and multi-layered structure of MoS~2~ greatly limits its applications in drug delivery [@bib0150], therefore, in this study, two-dimensional MoS~2~ nanosheets were prepared by the chemical exfoliation method according to the literature ([Fig. 2](#f0015){ref-type="fig"}). Although MoS~2~ nanosheets produced by this method increased its water solubility via reducing the size and the number of layers, they were only stable in water within 1 h at the room temperature ([Fig. 3F](#f0020){ref-type="fig"}). In order to further increase its water solubility, PEGylation was performed in this study. More Mo atoms were exposed on the surface of MoS~2~ nanosheets after the oleum treatment, and according to the metallic character of Mo atoms in MoS~2~ nanosheets, sulfhydryl substances were easily conjugated to the Mo, we firstly modified the MoS~2~ nanosheets with thioglycolic acid ([Fig. 2](#f0015){ref-type="fig"}). The successful conjugation of thioglycolic acid to the MoS~2~ nanosheets (MoS~2~-COOH) was confirmed by FT-IR spectrum ([Fig. 3A](#f0020){ref-type="fig"}), compared with the MoS~2~ nanosheets, MoS~2~-COOH gave a strong C = O (\~1710 cm^−1^) vibrations, indicating --COOH was introduced to MoS~2~ nanosheets. PEGylation was performed to improve the solubility and biocompatibility of MoS~2~ nanosheets, NH~2~-PEG2000-OCH~3~ were reacted with amino to form amide bonds and linked to the MoS~2~-COOH via carboxyl bonds ([Fig. 2](#f0015){ref-type="fig"}), the successful of PEGylation was also proved by FT-IR ([Fig. 3A](#f0020){ref-type="fig"}), compared with MoS~2~-COOH, MoS~2~-PEG gave the extra peaks at amide I(\~1662 cm^−1^) vibrations, amide III (\~1388 cm^−1^) vibrations and C-H (\~1127 cm^−1^) vibrations, and MoS~2~-PEG exhibited excellent stability in water ([Fig. 3F](#f0020){ref-type="fig"}).Fig. 3Characterization of MoS~2~-PEG/DOX. A) FT-IR spectrum of MoS~2~, MoS~2~-COOH and MoS~2~-PEG; B) and C) TEM images of MoS~2~ and MoS~2~-PEG/DOX; D) Zeta potential distribution of MoS~2~-PEG/DOX; E) UV-VIS spectrum of MoS~2~, MoS~2~-PEG and MoS~2~-PEG/DOX; F) MoS~2~ (a), MoS~2~-PEG (b), DOX (c) and MoS~2~-PEG/DOX (d) in water.Fig. 3

In this work, DOX, one of the most effective drugs against a wide range of cancers, was loaded onto MoS~2~-PEG through a physical adsorption. DOX loaded onto MoS~2~-PEG was confirmed by a strong absorption peak at around 495 nm over the background of MoS~2~-PEG in UV-VIS spectrum ([Fig. 3E](#f0020){ref-type="fig"}). MoS~2~-PEG/DOX was stable in water, PBS buffer, cell culture medium and plasma of mice over multiple weeks without significant aggregation ([Fig. 3F](#f0020){ref-type="fig"}). The amount of DOX loaded onto MoS~2~-PEG was calculated to be 69 wt%.

The morphology of MoS~2~ and MoS~2~-PEG/DOX nanosystem were characterized by TEM. As can be seen from TEM image ([Fig. 3B and C](#f0020){ref-type="fig"}), MoS~2~ had a large and multi-layered structure, while MoS~2~-PEG/DOX nanosheet was much smaller and obviously decreased the number of the layers, indicating that the chemical exfoliation and PEGylation were successful. MoS~2~-PEG/DOX showed a 2D structure with the size of 150 nm. The zeta potential of MoS~2~-PEG/DOX was −7.17 ± 1.8 mV, and zeta potential distribution were shown in [Fig. 3D](#f0020){ref-type="fig"}.

3.2. Increased temperature under NIR irradiation {#s0070}
------------------------------------------------

After NIR irradiation for 5 min, the temperature of MoS~2~-PEG (10 µg/ml, 1 W/cm^2^ or 2 W/cm^2^) samples increased 11.1 and 17.8 °C, respectively, while water increased 1.9 °C ([Fig. 4](#f0025){ref-type="fig"}). The temperature increase of MoS~2~-PEG showed NIR power density and NIR radiation time-dependent manners ([Fig. 4](#f0025){ref-type="fig"}), revealing that MoS~2~-PEG was an effective photothermal agent in cancer therapy.Fig. 4Temperature evolution of MoS~2~-PEG during continuous radiation by NIR at a power density of 1 W/cm^2^ or 2 W/cm^2^.Fig. 4

3.3. DOX release from MoS~2~-PEG/DOX {#s0075}
------------------------------------

Herein, the release behavior of DOX from MoS~2~-PEG/DOX was shown in [Fig. 5](#f0030){ref-type="fig"}, showing a sustain release over 48 h. In contrast, DOX release in DOX group was considerably fast, and almost 91.3% of the drug released after 12 h, indicating that interaction between MoS~2~-PEG and DOX plays a critical role in the release of drug.Fig. 5Release profiles of DOX from MoS~2~-PEG/DOX and DOX solution. Data were presented as mean ± standard deviation (*n* = 3).Fig. 5

3.4. X-ray imaging {#s0080}
------------------

MoS~2~ have a great potential as a contrast agent in X-ray imaging, in order to investigate the X-ray imaging ability of MoS~2~-PEG, MoS~2~-PEG in water with different concentrations were conducted on a small animal *in vivo* imaging system (Bruke), and the result was shown in [Fig. 6](#f0035){ref-type="fig"}. In order to further examine the X-ray imaging ability of MoS~2~-PEG, iohexol, a clinical X-ray contrast agent with a clinical dosage (240 mg/ml) was used in this study as a positive control, the X-ray images of MoS~2~-PEG (8 mg/ml) and iohexol (240 mg/ml) were also shown in [Fig. 6](#f0035){ref-type="fig"}. Compared with iohexol, MoS~2~-PEG exhibited stronger X-ray signal, suggesting that MoS~2~-PEG had a stronger X-ray imaging ability than iohexol, and the X-ray signal of MoS~2~-PEG was increasing with the concentration increased, revealing a concentration-dependent manner.Fig. 6X-ray images of iohexol and MoS~2~-PEG in water with different concentrations.Fig. 6

3.5. Cellular uptake {#s0085}
--------------------

To explore the uptake of MoS~2~-PEG/DOX by MCF-7 cells, we tracked DOX internalization into the cells through colocalization of DOX-signal (red fluorescence). As can be seen from [Fig. S3](#ec0020){ref-type="supplementary-material"}, cells incubated with MoS~2~-PEG/DOX for different time clearly revealed the time-dependent cellular uptake manner. Cells exposed to free DOX showed a stronger fluorescence intensity of DOX in the nucleus after 2 h of incubation, while in the case of MoS~2~-PEG/DOX, red fluorescence was observed mainly in the endosomes ([Fig. S3](#ec0020){ref-type="supplementary-material"}), indicating that MoS~2~-PEG/DOX were initially located within the endosomal intracellular compartments. After 6 h of incubation, the cells exposed to MoS~2~-PEG/DOX demonstrated an obvious increase of red fluorescence in the cell nucleus, suggesting that with the passage of time, on one hand, MoS~2~-PEG/DOX arrived at the cell cytoplasm from the endosomes gradually, on the other hand, DOX was released from MoS~2~-PEG/DOX to cytoplasm, then the intracellular DOX in the cytosol were rapidly transported to the nucleus and avidly bound to the chromosomal DNA \[44\]. This distinction in uptake could explain the difference in susceptibility of MoS~2~-PEG/DOX and DOX to MCF-7 cells.

3.6. *In vitro* PTT {#s0090}
-------------------

Cytotoxicity of MoS~2~-PEG is an important consideration for materials intended for *in vivo* application. Toward this goal, assessment of cell viability of MCF-7 cancer cells was examined. Incubation with MoS~2~-PEG showed that there were minimal decrease in cell viability (\<15%), even when the cells were incubated with 100 µg/mL of MoS~2~-PEG for 24 h ([Fig. S4](#ec0025){ref-type="supplementary-material"}), demonstrating that MoS~2~-PEG possess low toxicity without NIR laser irradiation. In order to further investigate the toxicity of MoS~2~-PEG with high concentration, the level of intracellular reactive oxygen species (ROS) was also determined in this study, from [Fig. S1](#ec0010){ref-type="supplementary-material"}, we can see that 100 µg/mL of MoS~2~-PEG did not significantly increase the intracellular ROS, and MoS~2~-PEG could not significantly induce the oxidative stress of MCF-7 cells, suggesting MoS~2~-PEG had little cytotoxicity to MCF-7 cells.

PTT usually employs hyperthermia agents to induce photothermal damage of tumor cells under NIR light [@bib0155]. Owningto its strong absorption in NIR window, MoS~2~-PEG was utilized for photothermal ablation of cancer cells under NIR in this study. MCF-7 cells were incubated with MoS~2~-PEG at different concentrations for 6 h and then exposed to a 808 nm NIR laser at a power density of 1 W/cm^2^ or 2 W/cm^2^ for 5 min. [Fig. 7A](#f0040){ref-type="fig"} showed that the viabilities of untreated cells were not noticeably affected under NIR laser (\>97%), however, MoS~2~-PEG incubated MCF-7 cells were largely killed after NIR irradiation, showing decreasing cell viabilities as the concentration of MoS~2~-PEG increased. Besides, the cell viabilities of MoS~2~-PEG/NIR (2 W/cm^2^) was much lower than that of 1 W/cm^2^, revealing that the PTT efficacy of MoS~2~-PEG showed a concentration-dependent manner, and a NIR power density-dependent manner. [Fig. 7B](#f0040){ref-type="fig"} showed that a large amount of cancer cells were killed in the NIR laser region, while the dead cells outside the NIR laser region were less, indicating that NIR laser based PTT had a good positioning property, and this advantage make PTT have a great potential application in the *in vivo* tumor therapy.Fig. 7(A) NIR thermal ablation of MCF-7 cells (NIR: 808 nm laser, 5 min). (B) Fluorescence images of PI (red, dead cells) stained cells treated with MoS~2~-PEG (10 µg/ml) for 6 h in NIR region (NIR: 808 nm laser, 2 W/cm^2^, 5 min) and No NIR region, the NIR region and No NIR region were in one cell culture dish. Data were presented as mean ± standard deviation (*n* = 6).Fig. 7

3.7. NIR induced endosome escape {#s0095}
--------------------------------

MoS~2~-PEG/DOX nanosheets entered the MCF-7 cells via endocytosis, when the cells were treated with MoS~2~-PEG/DOX (DOX concentration: 10 µg/ml, MoS~2~-PEG concentration: 14.5 µg/ml) for 2 h, the red fluorescence (DOX signal) was concentrated in the cells, indicating MoS~2~-PEG/DOX was mainly in the endosomes ([Fig. 8](#f0045){ref-type="fig"}), while after 5 min of NIR radiation (808 nm laser, 2 W/cm^2^), the DOX signal obviously spread to the entire cell ([Fig. 8](#f0045){ref-type="fig"}). In order to exclude the influence of DOX release from MoS~2~-PEG/DOX under NIR laser, a DOX release experiment under NIR laser was performed, and the result showed that the DOX release did not have significant change combined with NIR laser irradiation. Therefore, we inferred that MoS~2~-PEG/DOX could escape from endosome under NIR irradiation, and MoS~2~-PEG/DOX spread to the entire cell quickly. NIR induced endosome escape needs two conditions, the first one is MoS~2~-PEG/DOX must be close to the membrane of endosome, and we found that compared with PEG, MoS~2~ had a stronger adsorption capacity on phospholipid, this property of MoS~2~ make MoS~2~ based system have the ability of cling to even insert to the endosome membranes. The other condition is MoS~2~-PEG/DOX must generate a large amount of heat under NIR laser, and this was already proved in [section 3.2](#s0070){ref-type="sec"}. In summary, MoS~2~-PEG/DOX clung to the membrane of endosome, when the NIR radiation came, MoS~2~-PEG/DOX generated a large amount of heat, and the heat induced the rupture of the membrane, at last MoS~2~-PEG/DOX could escape from endosome. NIR induced endosome escape of MoS~2~-PEG/DOX reduced the loss and improved the therapeutic efficacy of DOX.Fig. 8Fluorescence images of MCF-7 cells incubated MoS~2~-PEG/DOX for 2 h with or without NIR laser radiation (NIR: 808 nm laser, 2 W/cm^2^, 5 min) (200×).Fig. 8

3.8. Photothermal-chemotherapy *in vitro* {#s0100}
-----------------------------------------

Recently, combination therapy is more and more popular in cancer therapy, for examples, photothermal-chemotherapy [@bib0160], photodynamic-chemotherapy [@bib0165], and combination therapy always displays higher efficiency than any single treatment, therefore MoS~2~-PEG/DOX was utilized for cancer photothermal-chemotherapy in this study. MCF-7 cells were incubated with DOX and MoS~2~-PEG/DOX at different concentrations for 6 h and then exposed to NIR at a power density of 2 W/cm^2^ for 5 min. The combination therapeutic efficiency was shown in [Fig. 9](#f0050){ref-type="fig"}. There was no significant difference in cell viability between DOX-treated and MoS~2~-PEG/DOX-treated cells. Compared with no NIR groups or DOX alone group, the NIR radiation greatly enhanced the cytotoxicity of MoS~2~-PEG/DOX especially in the concentration groups. The lower cell-killing ability in the low concentration groups could be attributed to insufficient MoS~2~-PEG to producing enough heat to kill cells. At a DOX concentration of 5 µg/ml with MoS~2~-PEG concentration of 7.3 µg/ml, the inhibition rate of MoS~2~-PEG/DOX/NIR was significantly increased to around 81.3%, while MoS~2~-PEG/DOX and MoS~2~-PEG/NIR (10 µg/ml) were around 58.2% and 59.3% respectively, indicating an enhanced cell-killing effect, thus, a synergistic therapeutic effect of PTT induced by MoS~2~-PEG and DOX was observed on MCF-7 cells. Besides PTT, NIR laser could also stimulate endosome escaping to improve the efficiency of DOX, this might be another reason for the higher therapeutic efficacy of MoS~2~-PEG/DOX/NIR than MoS~2~-PEG/DOX.Fig. 9Cell viability of different treatments on MCF-7 cells. For PTT: 808 nm laser, 2 W/cm^2^, 5 min. Data were presented as mean ± standard deviation (*n* = 6).Fig. 9

3.9. MCF-7 cells apoptosis {#s0105}
--------------------------

To further understand the therapeutic efficacy of combination treatment group, the cell apoptosis experiment was also investigated. DOX and MoS~2~-PEG/DOX treatment significantly enhanced the cell apoptosis (*P *\<* *0.05), while the PTT treatment groups significantly enhanced the cell necrotic (*P *\<* *0.05), the number of health cells in MoS~2~-PEG/DOX treatment group was around 2.2%, much less than the other groups ([Fig. 10](#f0055){ref-type="fig"}), showing the combination therapy was most effective, and the result was consistent with the cell viability studies.Fig. 10Cell apoptosis studies of different treatments on MCF-7 cells. DOX concentration: 5 µg/ml, MoS~2~-PEG/DOX concentration: 7.3 µg/ml; For PTT: 808 nm laser, 2 W/cm^2^, 5 min. Data were presented as mean ± standard deviation (*n* = 6) (200×).Fig. 10

3.10. Toxicity of MoS~2~-PEG *in vivo* {#s0110}
--------------------------------------

As MoS~2~ is a new material in biomedicine, its toxicity is the most important consideration for further applications. Therefore, we investigated the toxicity of MoS~2~-PEG in this study. For the acute toxicity, 120 mg/kg, 60 mg/kg and 10 mg/kg of MoS~2~-PEG were intravenously injected into tumor-bearing mice (6 mice per group), and the injection volume was 0.2 ml. No mouse died after injection for 5 d, even at a very high MoS~2~-PEG dosage (120 mg/kg), indicating that MoS~2~-PEG had a low toxicity *in vivo*. In order to further understand the injury especially the inflammation and liver damage induced by MoS~2~-PEG, long term toxicity was also performed. 20 mg/kg of MoS~2~-PEG were intravenously injected into tumor-bearing mice (6 mice per group) every 2 d for 14 d, no mouse died at the end, the number of hemocytes and the content of alanine aminotransferase (ALT) in blood after 14 d treatment were shown in [Fig. S5](#ec0030){ref-type="supplementary-material"}, the number of white blood cells (WBC), red blood cells (RBC) and platelets (PLT) in blood did not significantly increase, demonstrating that MoS~2~-PEG did not induce the obvious inflammation *in vivo*. The content of ALT in blood is an important indicator of liver damage, and the level of ALT directly reflects the degree of liver damage [@bib0170], [@bib0175], the content of ALT after treatment was shown in [Fig. S5](#ec0030){ref-type="supplementary-material"}B. Compared with the control group, the content of ALT in MoS~2~-PEG-treated group increased (*P *\<* *0.05), but the increased amount of ALT was little, indicating that MoS~2~-PEG (20 mg/kg) treatment for 14 d slightly induced the liver damage of the mice. In the following *in vivo* studies, the dosage of MoS~2~-PEG we used was 7.3 mg/kg, which was much lower than 20 mg/kg, so we thought the dosage of MoS~2~-PEG used in this study may not be noticeably toxic to mice.

3.11. Biodistribution studies {#s0115}
-----------------------------

In order to investigate the biodistribution behavior of MoS~2~-PEG, a near-infrared dye (IR783) was used to mark MoS~2~-PEG. The biodistribution of IR783 alone was shown in [Fig. S2](#ec0015){ref-type="supplementary-material"}. After injection of IR783 for 1 min, the fluorescence signal was mainly in liver, 30 min later, the signal was in liver and tumor, the fluorescence signal was mainly in bladder after 4 h of injection, indication IR783 was cleared by the body after injection for 4 h.

Meanwhile, the biodistribution of MoS~2~-PEG/IR783 was shown in [Fig. 11](#f0060){ref-type="fig"}, after injection for 1 min, the signal of MoS~2~-PEG/IR783 was mainly in liver, 30 min later, it was in tumor site, and increased from 30 min to 8 h after injection. Compared with 8 h, the signal of MoS~2~-PEG/IR783 in tumor at 24 h decreased, but still had a high level. Twenty-four hours after injection, the amount of MoS~2~-PEG/IR783 in heart, liver, spleen, lung, kidney and tumor was also shown in [Fig. 11](#f0060){ref-type="fig"}, stronger fluorescence signal was observed in tumor and liver, indicating MoS~2~-PEG was mainly in tumor and liver 24 h after injection, showing that MoS~2~-PEG could significantly accumulate in the tumor site via EPR effect, suggesting MoS~2~-PEG had a great potential in drug delivery for tumor targeting therapy. Eight hours after injection, more signal of MoS~2~-PEG/IR783 was observed in tumor than the other time points, so in the following *in vivo* tumor growth inhibition studies, the NIR laser irradiation time was set at 8 h after injection. The high distribution of MoS~2~-PEG in tumor and low distribution in heart, spleen, lung and kidney give MoS~2~-PEG a great advantage for antitumor drug delivery.Fig. 11The *in vivo* biodistribution of MoS~2~-PEG/IR783 for different times.Fig. 11

To understand tumor treatment efficacy of DOX and MoS~2~-PEG/DOX, the biodistribution of DOX was investigated ([Fig. 12](#f0065){ref-type="fig"}). MoS~2~-PEG/DOX showed noticeable DOX activity in blood at all the time points after injection, whereas DOX levels in the blood were much lower in the DOX group (*P* \< 0.01), indicating that MoS~2~-PEG/DOX significantly increased the blood circulation time of DOX *in vivo*. The DOX levels in tumor were sustained increasing from 30 min to 8 h after injection, and this result was consist with the distribution of MoS~2~-PEG, indicating that DOX and MoS~2~-PEG was one system *in vivo*. Compared with DOX, MoS~2~-PEG/DOX significantly decreased the distributions of DOX in heart, spleen and kidney, and this would greatly decrease the side effects of DOX to heart, spleen and kidney. Importantly, MoS~2~-PEG/DOX afforded much higher DOX uptake in tumor than DOX (*P *\<* *0.05). The DOX level in tumor of MoS~2~-PEG/DOX was higher than that of in DOX group by 5.4-fold at 8 h after injection and by 11.6-fold higher at 12 h after injection ([Fig. 12](#f0065){ref-type="fig"}). The ability of higher drug delivery efficiency to tumor by MoS~2~-PEG/DOX was striking and directly responsible for the higher tumor suppression efficacy than DOX.Fig. 12Distributions of DOX and MoS~2~-PEG/DOX in tumor bearing mice. Data were presented as mean ± standard deviation (*n* = 3).Fig. 12

3.12. Tumor growth inhibition *in vivo* {#s0120}
---------------------------------------

To investigate *in vivo* treatment efficacy of MoS~2~-PEG/DOX, comparative efficacy studies were conducted. The S180 tumor-bearing mice were divided into 7 groups and were treated according to protocols as summarized in method [section 2.7](#s0050){ref-type="sec"}. The changes of relative tumor volume as a function of time were plotted in [Fig. 13A](#f0070){ref-type="fig"}. The mice treated with NIR laser alone and MoS~2~-PEG without NIR laser irradiation did not show any therapeutic effect, suggesting that NIR laser and the blank carrier would not affect the tumor growth. Compared with MoS~2~-PEG (5.1 ± 0.44), the MoS~2~-PEG/NIR resulted in V/V~0~ of 3.4 ± 0.33, in order to further understand the therapeutic efficiency of PTT, a thermal effect of PTT in tumor site were investigate ([Fig. 13B](#f0070){ref-type="fig"}). Compared with before NIR irradiation, the tumor site irradiated for 5 min showed an obvious increase of temperature (\~10.7 °C). DOX had a relative tumor volume (V/V~0~) of 2.7 ± 0.26, while MoS~2~-PEG/DOX resulted in V/V~0~ of 1.3 ± 0.29, suggesting that MoS~2~-PEG/DOX could bring more DOX into the tumor site. MoS~2~-PEG/DOX/NIR had a V/V~0~ of 0.66 ± 0.21, and it is significantly more effective than the other therapeutic groups (*P *\<* *0.05). Remarkably synergistic enhanced therapeutic effect was observed in the combination treatment group.Fig. 13*In vivo* treatments (A) Tumor growth of mice in different treatment groups within 14 days; (B) Increased temperature in tumor under NIR radiation (808 nm, 2 W/cm^2^); (C) H&E stained tumor tissues harvested from the mice with different treatments (40×) and (D) Changes of body weight of mice in different groups during treatment. Data were presented as mean ± standard deviation (*n* = 6).Fig. 13

The therapeutic efficacy was also evaluated by H&E staining ([Fig. 13C](#f0070){ref-type="fig"}). Compared with the control group, a large amount of cell death in tumor tissue was observed in the mice treated with MoS~2~-PEG/DOX/NIR. The above results of H&E staining were consistent with the *in vivo* antitumor effect.

Allowing for high toxicity usually leads to weight loss, the body weight of all the groups were investigated. As can be seen from [Fig. 13D](#f0070){ref-type="fig"}, free DOX resulted in a significant decrease (2.00 ± 0.21) in body weight over the experimental period, while the other groups overall gained in body weight. These results indicated that MoS~2~-PEG/DOX increased the therapeutic index of DOX. Furthermore, MoS~2~-PEG/DOX can expectedly accumulate in tumor by escaping through the abnormally leaky tumor blood vessels and reduce the distribution in the normal organs [@bib0180], [@bib0185], and this could effectively reduce the side effects of DOX during the treatment.

3.13. *In vivo* X-ray imaging {#s0125}
-----------------------------

MoS~2~ had shown a great potential as the contrast agent for X-ray imaging, so in this study, MoS~2~-PEG/DOX was also used as a contrast agent for X-ray imaging. After injection of MoS~2~-PEG/DOX (DOX: 10 mg/kg, MoS~2~-PEG: 14.5 mg/kg) for 0.5, 4, 8 and 12 h, the X-ray images were shown in [Fig. 14](#f0075){ref-type="fig"}. Compared with control, the X-ray signals of MoS~2~-PEG/DOX in tumor were significantly increased after injection of MoS~2~-PEG/DOX for 0.5, 4 and 8 h, while the X-ray signal decreased at 12 h. The X-ray signals of MoS~2~-PEG/DOX were obviously observed in tumor after injection for 8 h, indicating that MoS~2~-PEG could accumulate in tumor, and have a great potential in tumor X-ray diagnostic applications. In order to further examine the X-ray imaging ability of MoS~2~-PEG *in vivo*, MoS~2~-PEG (8 mg/ml) and iohexol, a clinical X-ray contrast agent with a clinical dosage (240 mg/ml) were subcutaneously injected into a health mice at the same time, and the X-ray image was shown in [Fig. 15](#f0080){ref-type="fig"}, compared with iohexol, MoS~2~-PEG had a stronger X-ray imaging ability, demonstrating MoS~2~-PEG had a great potential as a X-ray contrast agent *in vivo*.Fig. 14X-ray images of a tumor-bearing mouse intravenous injection of MoS~2~-PEG/DOX (DOX: 10 mg/kg, MoS~2~-PEG: 14.5 mg/kg) for different times.Fig. 14Fig. 15X-ray images of a tumor-bearing mouse subcutaneous injection of MoS~2~-PEG (8 mg/ml, 0.1 ml) and iohexol (240 mg/ml, 0.1 ml).Fig. 15

4. Conclusion {#s0130}
=============

In summary, a new two-dimensional MoS~2~ based multifunctional drug delivery system (MoS~2~-PEG/DOX) was successfully developed. In this study, MoS~2~-PEG/DOX served not only as a tumor-targeting drug delivery system, but also as a strong photothermal agent and a powerful X-ray contrast agent. In the *in vitro* and *in vivo* studies, MoS~2~-PEG did not show noticeable toxic to mice even at very high dosages. MoS~2~-PEG/DOX exhibited excellent tumor-targeting efficacy, outstanding synergistic anti-cancer effect of photothermal and chemotherapy, NIR induced endosome escaping ability and X-ray imaging property, demonstrating that MoS~2~-PEG/DOX had a great potential for simultaneous diagnosis and combination therapy in cancer treatment.

Appendix. Supplementary material {#s0140}
================================

The following is the supplementary data to this article:Fig. S1Detection of intracellular ROS by DCFH-DA staining in MCF-7 cells (40×).Fig. S1

Fig. S2The *in vivo* biodistribution of IR783 for different times.Fig. S2

Fig. S3Fluorescence images of MCF-7 cells incubated with DOX and MoS~2~-PEG/DOX for 0.5, 2 and 6 h (200×).Fig. S3

Fig. S4Cytotoxicity of MoS~2~-PEG. Data were presented as mean ± standard deviation (n = 6).Fig. S4

Fig. S5Toxicity of MoS~2~-PEG *in vivo*. (A) The number of WBC, RBC and PLT in blood; (B) ALT in blood. Data were presented as mean ± standard deviation (n = 3).Fig. S5
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